Welcome to our dedicated page for Alto Neuroscience SEC filings (Ticker: ANRO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Alto Neuroscience filings document the regulatory record of a clinical-stage biopharmaceutical issuer developing precision medicines for neuropsychiatric disorders. Form 8-K reports cover operating and financial results, clinical updates for programs such as ALTO-101 and ALTO-207, and material definitive agreements tied to private placements of common stock and pre-funded warrants.
Proxy materials describe annual meeting matters, including director elections, auditor ratification and proposed amendments to the company’s equity incentive and employee stock purchase plans. The filings also identify ANRO common stock registered on the New York Stock Exchange and the company’s emerging growth company status.
Alto Neuroscience, Inc. (ANRO) announced a leadership change effective August 26, 2026. The Board promoted Nicholas C. Smith, previously Chief Financial Officer and Chief Business Officer, to President and Chief Financial Officer. Amit Etkin, M.D., Ph.D. remains Chief Executive Officer and continues to serve as the principal executive officer, while Mr. Smith is the principal financial officer.
Under a new Promotion and Retention Agreement, Mr. Smith is entitled to a cash Retention Payment totaling $6,000,000, with $3,000,000 payable within ten days of August 26, 2026 and $3,000,000 on the twelve-month anniversary of that date, subject to standard deductions and withholdings. If his employment ends for any reason, or for Cause by the company, before the two-year Retention Date, any unpaid portion is forfeited and any paid portion is subject to recoupment within 30 days, except when the company terminates him without Cause or his employment ends due to death or Disability, in which case any unpaid portion will be paid.
Alto Neuroscience, Inc. has an institutional holder group led by Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. reporting beneficial ownership of 4,176,711 shares of common stock, equal to 9.99% of the company’s 39,242,104 shares outstanding as of August 7, 2026.
The Master Fund directly holds 1,609,893 shares and 2,898,854 pre-funded warrants exercisable at $0.0001 per share. A “Beneficial Ownership Limitation” caps exercisability so that, as of this report, only 2,566,818 warrant shares are counted toward beneficial ownership, keeping the group at the 9.99% threshold. Perceptive Advisors serves as investment manager to the Master Fund, and Joseph Edelman is the managing member of Perceptive Advisors.
Vestal Point Capital, LP and Ryan Wilder report beneficial ownership of Alto Neuroscience, Inc. common stock on an amended Schedule 13G (Amendment No. 2). They report beneficial ownership of 785,000 shares of common stock, representing 2.2% of the class, held through a fund and a managed account advised by Vestal Point Capital.
All 785,000 shares are reported with shared voting and dispositive power and no sole power. The ownership percentage is based on 35,093,940 shares outstanding as of May 8, 2026, as stated in Alto Neuroscience’s Form 10-Q. The filers state that the Schedule 13G should not be construed as an admission of beneficial ownership for Section 13 purposes and confirm they own 5% or less of the class.
Sirenia Capital Management LP and Alex Silverstein report beneficial ownership of Alto Neuroscience, Inc. common stock. They collectively report 2,219,568 shares of Common Stock, including 787,043 shares issuable upon exercise of warrants, representing 6.2% of the class based on 35,093,940 shares outstanding as of May 8, 2026. Voting and dispositive power over these shares is shared, with no sole voting or dispositive power reported. SILV Fund, Ltd. has the right to receive dividends or sale proceeds for more than 5% of the outstanding Common Stock.
Alto Neuroscience, Inc. reported a larger net loss while significantly strengthening its balance sheet for the quarter ended June 30, 2026. Cash and cash equivalents rose to $243.7 million, up from $176.5 million at year-end 2025, driven mainly by a March 2026 private placement of common stock and pre-funded warrants that generated $114.8 million in net proceeds, plus loan conversions.
Operating expenses increased as the pipeline advanced. For the quarter, research and development expense grew to $22.1 million from $13.1 million, and general and administrative expense to $7.0 million from $5.6 million, producing a loss from operations of $29.1 million. Quarterly net loss was $27.6 million versus $17.7 million a year earlier; six‑month net loss was $53.9 million.
Net cash used in operating activities for the first half of 2026 was $46.9 million. Alto ended the period with total assets of $254.1 million, total liabilities of $34.8 million (including a $15.0 million term loan and a $2.5 million fair‑valued convertible grant), and stockholders’ equity of $219.2 million, supporting ongoing clinical programs such as ALTO‑207, ALTO‑300, ALTO‑100, ALTO‑101, and ALTO‑203.
Alto Neuroscience, Inc. reported second quarter 2026 results and pipeline updates focused on its lead program ALTO-207 for treatment-resistant depression. The company expanded ALTO-207 development to include a planned Phase 3 monotherapy trial in addition to an ongoing potentially registrational Phase 2b adjunctive trial, with topline Phase 2b data expected in 2H 2027. Independent data published in Nature Medicine reinforced the dopaminergic mechanism underlying ALTO-207 and showed significant effects on anhedonia. Enrollment continues in Phase 2b trials of ALTO-300 in major depressive disorder and ALTO-100 in bipolar depression, with data expected in 2027.
Alto completed an approximately $100 million registered direct offering in July 2026, resulting in pro forma cash of about $338 million, which the company expects to fund planned operations through 2030. As of June 30, 2026, cash, cash equivalents, and restricted cash were $244.2 million. For the quarter, research and development expenses rose to $22.1 million and general and administrative expenses to $7.0 million, leading to a net loss of $27.6 million compared to $17.7 million a year earlier.
BlackRock, Inc. reports beneficial ownership of common stock of Alto Neuroscience Inc. BlackRock and certain of its business units hold 2,104,406 shares of Alto Neuroscience common stock, representing 6.0% of the class.
BlackRock has sole voting power over 2,077,542 shares and sole dispositive power over 2,104,406 shares, with no shared voting or dispositive power. Various underlying clients have rights to dividends or sale proceeds, but no single client holds more than five percent of Alto Neuroscience’s outstanding common shares.
Alto Neuroscience, Inc. has a significant shareholder group led by EcoR1 Capital. EcoR1 Capital, LLC and its control person, Oleg Nodelman, each report beneficial ownership of 2,232,000 shares of Alto Neuroscience common stock, representing 5.8% of the class. EcoR1 Capital Fund Qualified, L.P. reports beneficial ownership of 2,065,935 shares, or 5.3% of the common stock. These percentages are calculated using 38,829,167 shares outstanding following the closing of an offering described in a July 14, 2026 prospectus. The reporting persons have no sole voting or dispositive power over the shares but share voting and dispositive power in the amounts reported. They state that the securities were acquired and are held without the purpose or effect of changing or influencing control of Alto Neuroscience.
Alto Neuroscience, Inc. entered into an underwriting agreement with BofA Securities, as representative of several underwriters, to issue and sell 3,776,436 shares of common stock in an underwritten registered direct offering under an effective shelf registration statement. The shares are priced at $26.48 per share, and the company estimates net proceeds of approximately $93.9 million after underwriting discounts, commissions and offering expenses.
The closing is expected on July 14, 2026, subject to customary conditions. Alto Neuroscience plans to use the net proceeds, together with existing cash and cash equivalents, to accelerate and expand clinical development of ALTO-207, including a planned additional Phase 3 monotherapy trial in treatment-resistant depression, and for general working capital.
Alto Neuroscience, Inc. is conducting a primary underwritten offering of 3,776,436 shares of common stock at $26.48 per share, for an aggregate offering price of $100,000,025.28. Underwriting discounts are $1.4564 per share, yielding $94,500,023.89 in proceeds before expenses and estimated net proceeds of approximately $93.9 million.
The company plans to use the net proceeds, together with existing cash and cash equivalents, to accelerate and expand clinical development of ALTO-207, including an additional planned Phase 3 monotherapy trial in treatment resistant depression, and for general working capital purposes.
Cash, cash equivalents and restricted cash were preliminarily estimated at $244.2 million as of June 30, 2026. Shares outstanding are expected to increase from 35,052,731 as of March 31, 2026 to 38,829,167 after the offering, which the company calculates will result in immediate dilution of $17.80 per share to new investors relative to the adjusted net tangible book value.